Clene Inc. secures additional NIH grant funds for ALS therapy

Salt Lake City-based pharmaceutical company Clene Inc. has amended its grant subaward with Columbia University, securing up to $8 million in additional funding for the second year of its amyotrophic lateral sclerosis (ALS) treatment program. The amendment, disclosed in a recent SEC filing, extends the financial support for the period from September 1, 2024, to August 31, 2025.

This financial boost is part of the National Institute of Health's (NIH) $45.1 million grant, initially announced on October 5, 2023, under the Accelerating Access to Critical Therapies for ALS Act. Clene Inc., along with its subsidiary Clene Nanomedicine, Inc., collaborates with Columbia University and Synapticure, a specialized neurology clinic, on the Expanded Access Program (ACT-EAP) for CNM-Au8, a treatment for ALS.

You May Also Be Interested In

• BofA Securities Upgrades Fomento Economico Mexicano (FMX) to Buy
• Latigo Biotherapeutics files for Nasdaq IPO at up to $18 per share
• Procore prices upsized $825M convertible notes due 2031